Woodline Partners’s Bright Minds Biosciences DRUG Stock Holding History
Bought
Maintained
Sold
Other funds holding DRUG
Woodline Partners's DRUG Position: Q3 2026 in Review
Woodline Partners held its Bright Minds Biosciences (DRUG) position steady in Q3 2026 at 45,668 shares worth $2.28M. The position accounts for 0.01% of the portfolio, ranked #865.
Woodline Partners first reported a position in DRUG in Q1 2026 and has held it in 3 quarters since. The position peaked at $3.33M in Q1 2026. 110 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.
- Woodline Partners held 45,668 shares of Bright Minds Biosciences worth $2.28M as of Q3 2026.
- Woodline Partners left its Bright Minds Biosciences share count unchanged in Q3 2026.
- Bright Minds Biosciences made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #865 holding.
- Woodline Partners first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 3 quarters since.
- Woodline Partners's Bright Minds Biosciences position peaked at $3.33M in Q1 2026.
- 110 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.